Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP542509.RAYioQS3Lbn32KG9kYo3JtQPaejEL6mQYEryf0EWfC3SI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP542509.RAYioQS3Lbn32KG9kYo3JtQPaejEL6mQYEryf0EWfC3SI130_assertion type Assertion NP542509.RAYioQS3Lbn32KG9kYo3JtQPaejEL6mQYEryf0EWfC3SI130_head.
- NP542509.RAYioQS3Lbn32KG9kYo3JtQPaejEL6mQYEryf0EWfC3SI130_assertion description "[The current controversy concerning optimal hemoglobin levels in chronic kidney disease patients treated with ESAs and the potential negative clinical outcomes of ESA treatment in cancer reinforces the need for cautious evaluation of the pleiotropic effects of ESAs in non-erythroid tissues.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP542509.RAYioQS3Lbn32KG9kYo3JtQPaejEL6mQYEryf0EWfC3SI130_provenance.
- NP542509.RAYioQS3Lbn32KG9kYo3JtQPaejEL6mQYEryf0EWfC3SI130_assertion evidence source_evidence_literature NP542509.RAYioQS3Lbn32KG9kYo3JtQPaejEL6mQYEryf0EWfC3SI130_provenance.
- NP542509.RAYioQS3Lbn32KG9kYo3JtQPaejEL6mQYEryf0EWfC3SI130_assertion SIO_000772 17656101 NP542509.RAYioQS3Lbn32KG9kYo3JtQPaejEL6mQYEryf0EWfC3SI130_provenance.
- NP542509.RAYioQS3Lbn32KG9kYo3JtQPaejEL6mQYEryf0EWfC3SI130_assertion wasDerivedFrom befree-20150227 NP542509.RAYioQS3Lbn32KG9kYo3JtQPaejEL6mQYEryf0EWfC3SI130_provenance.
- NP542509.RAYioQS3Lbn32KG9kYo3JtQPaejEL6mQYEryf0EWfC3SI130_assertion wasGeneratedBy ECO_0000203 NP542509.RAYioQS3Lbn32KG9kYo3JtQPaejEL6mQYEryf0EWfC3SI130_provenance.